DiagnosDGNOF +1.00%16 OCF Yield % is -12.75 as of Jul. 04, 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 684 Healthcare Providers & Services companies, Diagnos ranks worse than 86.84% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Diagnos's OCF Yield % or its related term are showing as below:
DGNOF'
s OCF Yield % Range Over the Past 10 Years
Min: -73.1 Med: -11.31 Max: -3.31
Current: -12.75
During the past 13 years, the highest OCF Yield % of Diagnos was -3.31%. The lowest was -73.10%. And the median was -11.31%.
DGNOF's OCF Yield % is ranked worse than 86.84% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 5.48
vs DGNOF: -12.75
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Diagnos OCF Yield % Related Terms
Diagnos OCF Yield % Historical Data
* Premium members only.
The historical data trend for Diagnos's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnos's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos OCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Diagnos's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnos (DGNOF) has a OCF Yield % of -12.75 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Diagnos and its competitors. According to the industry distribution chart, Diagnos ranks #594 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 86.8%.
Is Diagnos' OCF Yield % too high?
Diagnos' current OCF Yield % is -12.75. Based on the distribution chart, Diagnos ranks #594 out of 684 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' OCF Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #594 out of 684 companies for OCF Yield %. This places Diagnos in the lower half of its industry. The industry median OCF Yield % is 5.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Healthcare Providers & Services company?
The median OCF Yield % among Healthcare Providers & Services companies is 5.48, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median OCF Yield % is 5.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current OCF Yield % is -12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current OCF Yield % is -12.75. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Diagnos (DGNOF), the current OCF Yield % is -12.75 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
OCF Yield %: -12.75
GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score
Get the complete analysis for DGNOF
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
